General Info

XOMA is a pioneer and leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. The company has a royalty interest in RAPTIVA, a monoclonal antibody product marketed worldwide to treat moderate-to-severe plaque psoriasis. Its discovery and development capabilities include antibody phage display, bacterial cell expression, and human engineering technologies, plus a fully integrated drug development infrastructure. XOMA s development collaborators include Aphton Corporation, Chiron Corporation and Lexicon Genetics Incorporated. The company pipeline also includes proprietary programs in preclinical and clinical development. It trades on NASDAQ under the symbol XOMA. The company is headquartered in Berkeley, Calif.